Validating the use of the “aging men’s symptoms score” as screening tool for anxiety and depression in non-metastatic prostate cancer patients receiving androgen deprivation therapy

2018 ◽  
Vol 17 (2) ◽  
pp. e89-e90
Author(s):  
M. O’Cathail ◽  
S. Hosni ◽  
J. Little ◽  
A. Cox ◽  
S. Santhanam
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Screening Tool ◽  
Androgen Deprivation ◽  
Anxiety And Depression

scholarly journals Modified J‐CAPRA scoring system in predicting treatment outcomes of metastatic prostate cancer patients undergoing androgen deprivation therapy

2020 ◽  
Vol 9 (24) ◽  
pp. 9346-9352
Author(s):  
Jasmine Lim ◽  
Shiro Hinotsu ◽  
Mizuki Onozawa ◽  
Rohan Malek ◽  
Murali Sundram ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Treatment Outcomes ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Scoring System ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation

Usefulness of Prostate-Specific Antigen Nadir as Predictor of Androgen-Independent Progression of Metastatic Prostate Cancer

2005 ◽  
Vol 20 (4) ◽  
pp. 209-216 ◽  
Author(s):  
J. Morote ◽  
S. Esquena ◽  
J.M. Abascal ◽  
E. Trilla ◽  
L. Cecchini ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prognostic Factors ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Gleason Score ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation ◽  
Bone Involvement ◽  
Free Survival ◽  
Psa Nadir

The objective of this study was to analyze the value of the nadir level of prostate-specific antigen (PSA) to predict androgen-independent progression (AIP) in metastatic prostate cancer patients after androgen deprivation therapy. In a group of 185 metastatic prostate cancer patients who received androgen deprivation therapy serum PSA was determined every three months until AIP occurred. Multiple regression analysis was performed to define independent clinical and PSA-related predictors of AIP. AIP was assumed to be present after two consecutive increases in serum PSA after the PSA nadir. Independent predictors of the duration of AIP-free survival (less than 12 months versus more than 12 months) were the extent of bone involvement (six or fewer hot spots versus more than six) with an odds ratio (O.R.) of 3.95, Gleason score (7 or less versus more than 7) with an O.R. of 3.47, and PSA nadir (2 μg/L or less versus more than 2 μg/L) with an O.R. of 14.63. AIP was independently predicted by the extent of bone involvement with an O.R. of 1.72, Gleason score with an O.R. of 1.74, PSA nadir with an O.R. of 3.22, and time to reach the PSA nadir (9 months or less versus more than 9 months) with an O.R. of 2.84. When patients were stratified according to these predictors, those with three good prognostic factors had a median AIP-free survival of 58 months while those with two, one or no good prognostic factors had a median AIP-free survival of 19 months, 12 months and 7 months, respectively. We conclude that the PSA nadir seems to be a good predictor of AIP in patients with metastatic prostate cancer after androgen deprivation therapy. Time to PSA nadir, extent of bone involvement and Gleason score are also independent predictors. The combination of these prognostic factors allows to stratify metastatic prostate cancer patients for the prediction of AIP.

675 Survival and metastases among non-metastatic prostate cancer patients treated with androgen deprivation therapy (ADT) in Denmark, 1997–2010

2013 ◽  
Vol 12 (1) ◽  
pp. e675-e676
Author(s):  
M. Nguyen-Nielsen ◽  
M.L. Maegbaek ◽  
R.K. Hernandez ◽  
H.T. Sørensen ◽  
V. Ehrenstein ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation
Sign in / Sign up

Export Citation Format

Share Document